举世瞩目的以色列接种辉瑞Pfizer和阿联酋接种辉瑞Pfizer和国药SinoPharm疫苗进展: 12月20日 177% : 222%,阳性率0.78% :0.03%

阿联酋的接种率只有66%。
以色列已经是100%。

比较两国感染率下降的幅度,不能得出结论中国的灭活疫苗效果比mRNA疫苗的效果差。

另外,阿联酋用了四种疫苗。
我还没有仔细看这篇文章,直觉他的结论有不少问题。加拿大和印度的改善没法算是疫苗的功劳,阿联酋各方面的数据都不比以色列差。
 
1616123455370.png



1616123510312.png
 
很好,也许是以色列的疫苗逐渐发挥出越来越大的效果,但是以色列之所以阳性率一直比阿联酋高很多,是因为阿联酋的测试数量大大高于以色列,尤其是今天超过以色列的33倍,今天以色列仅测试6千人,而阿联酋的测试人数将近20万,阳性率以色列是 22.8,阿联酋是 1.1.

当然也许以色列大多数人已经接种疫苗,不需要进行测试了。

1616125226753.png
1616125588197.png
 
很好,也许是以色列的疫苗逐渐发挥出越来越大的效果,但是以色列之所以阳性率一直比阿联酋高很多,是因为阿联酋的测试数量大大高于以色列,尤其是今天超过以色列的33倍,今天以色列仅测试6千人,而阿联酋的测试人数将近20万,阳性率以色列是 22.8,阿联酋是 1.1.

当然也许以色列大多数人已经接种疫苗,不需要进行测试了。

浏览附件964504浏览附件964506

还不死心?七日平均以色列马上就只有UAE的一半了:)
 
还不死心?七日平均以色列马上就只有UAE的一半了:)
咱们各看各好不好?你喜欢看哪个指标我绝不干涉。
 
你是想发掘事实还是想维持梦境?:)
我发的都是数据图表,哪个在梦境?我没有否认最近一周以色列的确诊人数低于阿联酋。如果这是由于疫苗的效果,这很好,这是此楼所关注的焦点,我会一直继续下去。
 
我发的都是数据图表,哪个在梦境?我没有否认最近一周以色列的确诊人数低于阿联酋。如果这是由于疫苗的效果,这很好,这是此楼所关注的焦点,我会一直继续下去。
好!
 

以色列的死亡占人口比例是全球的1.9倍,峰值(1月25日,26日为4.1倍。)​

Israel's COVID-19 Vaccination Rollout Is Slowing at a Critical Moment. That's a Warning for the Rest of Us​

Nurse Yaffa Zigel vaccinates a patient at Leumit Vaccination Center, Tel Aviv, on Feb. 21

Nurse Yaffa Zigel vaccinates a patient at Leumit Vaccination Center, Tel Aviv, on Feb. 21

Amit Elkayam
BY TARA LAW

MARCH 19, 2021 10:18 AM EDT

Now that nearly 60% of Israel’s roughly 9 million residents have gotten at least one shot of a COVID-19 vaccine, the New Jersey-sized Middle Eastern country is offering the rest of the world an enviable glimpse of a future where most people are inoculated against the coronavirus. While it’s still too early to tell the full extent to which vaccination is having an effect there, Israel’s rate of virus-related deaths has dropped faster than global figures since it started vaccinating (see chart below and methodology at bottom). Meanwhile, the latest real-world evidence collected in Israel suggests the Pfizer-BioNTech vaccine—the country’s most commonly administered shot—is preventing nearly 99% of deaths from COVID-19, while also curbing viral spread.

1616210901030.png


Israel’s mass vaccination efforts got off to an impressive start, with more than 10% of the population receiving their first dose fewer than two weeks into the national vaccination campaign. By comparison, it took the U.S. 57 days to reach the same mark, the U.K. 45 days, and the European Union still hasn’t matched it. Today, Israel is the worldwide leader in vaccinations per capita, at 108 doses administered for every 100 people, per the New York Times (the Pfizer vaccine requires two doses).

But Israel’s breakneck rollout is beginning to slow, according to data from the Israeli Ministry of Health. While the country was administering first doses to as much as 1.5% of its population every day in early January, it’s now distributing fewer than 0.2% of initial doses daily.

That’s a problem, as Israel remains short of the 70% mark that public health experts say is the minimum required level for mass vaccination to turn the tide against the pandemic in a given country.

A closer look at the data reveals that not everyone in Israel has benefited equally from the vaccine rollout. Only 67% of Arab-Israelis and 70% of Israeli Haredi Jews (a group sometimes referred to as “ultra-Orthodox” Jews) over 16 were vaccinated or had recovered from COVID-19 as of March 4, compared to 90% of the rest of the population, according to data shared by Weizmann Institute computational biologist Eran Segal. However, Israel has recently had success targeting older—and thus more vulnerable—members of those communities. By March 4, 84% of Arab-Israelis and about 80% of Haredi Israelis over 50 were vaccinated, up from 68% and 72% respectively on Feb. 22, according to Segal’s data.

Aside from being the right thing to do on moral grounds, better vaccinating these groups could push Israel over the critical nationwide 70% mark. To achieve that goal, Israeli public health officials have been working to address two major problems: vaccine hesitancy among these and other groups, and a failure to reach some residents who live in remote areas with less access to vaccination facilities and trustworthy information. Its efforts could be instructive for the U.S., which is also struggling with comparatively lower vaccination rates among some demographic groups, and for similar reasons. The Centers for Disease Control and Prevention only has race and ethnicity data for just over half of the vaccinations administered in the U.S. as of March 15, but of those shots, nearly two thirds have gone to white Americans, while less than 10% have gone to Hispanic or Black Americans, who make up 18.5% and 13.4% of the U.S. population, respectively.

In Israel, some groups are more vaccine hesitant or skeptical than others. A January survey from the Social Policy Institute at Washington University in St. Louis found that 51% of yet-unvaccinated Arab-Israelis and 42% of Israeli Haredi Jews weren’t planning to get the shot, for instance, compared to just 34% of those who identified as either secular, cultural, or Reform Jews. There’s a similar phenomenon occurring in the U.S., where 42% of Republicans, 35% of rural residents and 35% of Black Americans said in December that they probably or definitely will not get the vaccine, compared to just 27% of the general public, per the Kaiser Family Foundation.

Only 29% of Israelis overall say they trust the government, while 25% of Arab-Israelis say the same, according to the 2020 Israeli Democracy Index. Some Arab-Israelis have been angered by discrimination and hostility towards their community, as well as by Israel’s treatment of the Palestinian territories like the West Bank and Gaza, where vaccinations have barely begun. Some Haredi Israelis, meanwhile, feel their culture and belief system is incompatible with what they view as Israel’s secular mainstream society, and many trust religious leaders over secular authorities. During the COVID-19 outbreak, Haredi groups have butted heads with government officials over lockdowns and restrictions; some have gathered for holidays and funerals despite restrictions against large groups. In an August poll, more than half of Israeli Haredim said their community’s trust in the current government was shaken amid the pandemic.

All of this is relevant to the vaccine rollout, experts say, because people who distrust the government for any reason may be less likely to listen when it pushes a vaccine. “Sometimes, politics really goes against the interest of public health,” says Hadas Ziv, head of projects and ethics for medical nonprofit Physicians for Human Rights Israel. Arab-Israelis, Haredi Israelis and other Israelis have also been exposed to anti-vaccination messaging and misinformation on social media platforms like WhatsApp and via word of mouth.

Some of the U.S. groups expressing relatively high vaccine hesitancy are similarly distrustful of the government—just 9% of Black Americans told Pew in 2019 that they trust Washington all or most of the time, compared to 17% of white Americans, for instance. Former U.S. President Donald Trump’s politicization of the virus and vaccine approval sowed further skepticism, experts say—after Trump promised a vaccine by last year’s Election Day, about 62% of Americans told Kaiser that they were worried a shot would be green-lit for political reasons before it was proven safe and effective. Moreover, inadequate access to care and longstanding mistreatment by medical institutions has contributed to distrust of healthcare providers among Black Americans and other non-white groups. Misinformation about COVID-19 vaccines, meanwhile, runs rampant on American social media networks, as it does in Israeli online communities. While vaccine hesitancy has been dropping in recent weeks, according to a TIME/Harris Poll conducted earlier this month, it remains a major issue for U.S. health officials.

To help solve the credibility issue, Israeli public health officials have turned to trusted voices in communities with low uptake. This approach “turns the gaze of the community to the experts to the local expert—and then the local expert does the persuasion,” says Saad Omer, director of the Yale Institute for Global Health. In December, Aida Touma-Sliman, an Arab-Israeli member of Israel’s national legislature, tweeted a picture of herself being vaccinated to encourage other Arab-Israelis to do the same. “As someone who is very well known as part of the opposition, saying that in this situation, do not follow your mistrust of the government, but follow the best interest of your health—it sounds more like something to believe, than coming from Netanyahu: that despite my opposition, I am telling you, you should do it,” she says, referencing Israeli Prime Minister Benjamin Netanyahu. Yitzchak Zilberstein, a prominent ultra-Orthodox rabbi, shared a similar message with his community in December. “The risk of the vaccine is minimal compared to the many risks of the corona epidemic,” he wrote. Prominent Americans from Michelle Obama to Dolly Parton have similarly shared photos of themselves getting the vaccine in recent days.

Access is also emerging as an increasingly vital issue in Israel. Many of the country’s 9 million people live in urban centers, like Jerusalem and Tel Aviv; it’s been relatively easy for people there to walk into a vaccination site and get the jab. However, it’s been more challenging for the country to vaccinate people in historically underserved areas and communities, which are often largely Arab. “You can’t have places to get it in every tiny village,” says Orna Baron-Epel, a professor of health promotion at the University of Haifa. Similar patterns are playing out in the U.S., where access is suppressing vaccination rates in many predominantly Black neighborhoods, for instance.

Israel has recently been working to make the vaccine easier to get across the country. Aiman Saif, a former government official who’s been tapped to lead Israel’s COVID-19 response among Arab groups, told Jewish-American news outlet The Forward in February that Israel boosted the number of vaccination locations in Arab-majority areas from five or six to over 50, while also adding 30 buses as mobile vaccination stations. Leaders in Israeli Orthodox communities have organized vaccination drives and seminars at religious schools and other locations to boost uptake as well. In the U.S., health systems and local governments have deployed mobile vaccination clinics in rural areas and high density, low-income areas, and the Biden Administration has spearheaded efforts to distribute vaccines at community health centers serving low-income and minority patients.

Although Israel has shown that a lot can be done to reduce vaccine hesitancy and improve access, public health outreach to each of these groups must make up for decades of lost trust. While Israel has been making inroads in vaccinating some of the most vulnerable members of underserved groups, critics say leaders there were too slow to address these often predictable problems. Baron-Epel, for one, fears the government failed to invest enough resources in Arab communities earlier on, in particular. “The ideas are good, what they’re doing is good,” she says. “But it’s not enough, you know, and not fast enough.” The key lesson from Israel for the U.S. and other countries, then, may be a challenging one: hesitancy and access need to be addressed well before they become stumbling blocks late in the vaccine rollout.

Methodology note: The number of COVID-19 deaths in Israel peaked on Jan. 25 at 0.74 fatalities per 100,000 residents, compared to a global peak of 0.18 one day later, according to data from the Johns Hopkins Center for Systems Science and Engineering. While Israel’s peak value was much higher than the global average, its death rate has declined at a much steeper rate since the peak, though it’s too soon to know to what degree this can be attributed to vaccinations. For the sake of comparison, the first chart above presents both Israeli and global deaths as a percentage of the peak value—what’s called “normalizing” the data—so they can be easily compared.

—With reporting by Chris Wilson

 
最后编辑:
MARCH 19, 2021 10:18 AM EDT

Now that nearly 60% of Israel’s roughly 9 million residents have gotten at least one shot of a COVID-19

记得以色列不是已经接种达到100%了吗?
 
记得以色列不是已经接种达到100%了吗?
是每百人多少针,所以这个群体免疫的目标是140%,相当于70%打两针。最高值是200%。
 
是每百人多少针,所以这个群体免疫的目标是140%,相当于70%打两针。最高值是200%。



这样啊,太误导了。

应该用 至少一针的百分数和已经两针的百分数。
 
这样啊,太误导了。

应该用 至少一针的百分数和已经两针的百分数。
开始时,我也没有太注意,值得超过100%以后才发现,后来的表加了这三项:百人这的总针数,至少一针数,两针数。大体后两项相加应当等于第一项。
 
国家
Country​
百人中接种总针数 Percentage总接种针数 (百万)
Total Number (millions)
接种第一针人口百分数 Percentage接种第一针人数 (百万)
Total Number (millions)
已接种两针者百分数Fully Vaccinated %已接种两针人数(百万)
Fully Vaccinated (millions)
阳性率
Positive Rate %
日期
Date
阳性率
Positive Rate %
变化率 Change Percentage
以色列 Israel​
111.549.6559.65.1652.04.5010.3Feb. 12.3- 78%
阿联酋 UAE​
72.037.1235.2 (Feb. 23)3.48 (Feb. 23)22.12.192.4Jan. 190.9- 63%
加拿大 CANADA​
9.883.738.23.111.60.6218.9Jan. 293.2- 64%
英国 UK​
41.6528.2738.726.263.02.0112.8Jan. 40.4- 97%
美国 USA​
35.38118.3123.177.2312.541.9314.6Jan. 75.9- 60%
中国 China​
4.5164.98?
印度 India​
3.0542.062.534.840.57.221.9Feb. 13.4+ 79%
世界 World​
5.40420.693.2251.841.397.61

1616279062668.png
1616279080225.png

阳性率下降最多的两个国家是:英国和以色列。

以色列从2月1日峰值10.3%,现在已经低于原本比较低的加拿大为2.3%,50天下降 78% 。

英国从1月4日峰值12.8%,现在阳性率仅0.4%,75天下降 97%。

印度从1月15才开始打疫苗,最快最早见效也要到2月1日,50天后的阳性率却从1.9 升到 3.4,增加 79%。

1616282988951.png
1616283180843.png
 
最后编辑:

可能的新冠终结者:卡介苗​


来源: 朱头山 于 2021-03-21 06:36:00
目前新冠疫苗接种在全世界如火如荼地开展了,感染率和死亡率出现了一个明显的降幅,全世界都在开始乐观的预测新冠将在今年夏天,至迟今年年末结束时,疫情数据又开始转坏。南美,印度等国的疫情开始明显恶化,欧洲大陆和加拿大似乎出现了第三波,美国尽管疫苗接种的速度都在每天200万以上,有一天甚至达到600万,但感染率和死亡率的下降不如预期,接种的排头兵以色列的数据也出现了僵持。

根据以色列,英国和美国的一些对照研究数据,疫苗的效果还是很肯定的,无论是美国的mRNA疫苗,还是英国的阿斯利康疫苗,都在实际应用中展示了明显的保护作用。但这类新型疫苗,产生的抗体比较特异性,一旦病毒出现变异,可能就会失效。目前还没有证据证明,新型疫苗可以诱导细胞免疫。新型疫苗都是在体内诱导免疫,可能不会产生可以阻断粘膜接触的IgA,从而使得疫苗无法防止传染和被传染。还有,新型疫苗无法激发人体最强大的非特异免疫系统(innate immune)。这些都使得新型疫苗可能不那么强大,适应性也不太好,这是新事物都会出现的问题。

有个冷门的临床试验正在进行中,而且进展到第三期,BCG Vaccination to Prevent COVID-19 - Full Text View - ClinicalTrials.gov

这就是BCG(卡介苗)预防新冠的临床试验。

在1882年,德国微生物学家罗伯特·科赫发现了导致结核病的“罪魁祸首”——结核分枝杆菌。到了1907年,两名法国微生物学家又从牛身上分离了一种结核分枝杆菌,经过漫长的试验,研制出了一种能在人体内引发免疫反应的特殊菌株,促进了卡介苗的诞生。卡介苗是一种“老疫苗”了,它对儿童期脑膜炎与散播性结核病具有保护作用。我国要求新生儿应普遍接种卡介苗,因此你手臂上的小小疤痕,就是接种卡介苗留下的(也有人不留疤)

今年3月,在预印本平台MedRxiv上(该平台文章未经审评,不属证实发布),有科学家发现了一个有意思的现象:在没普及接种卡介苗的5个中高收入国家中(意大利、美国、黎巴嫩、荷兰、比利时),新冠肺炎百万感染率为264.9,百万死亡率为16.39;而在其他普及接种卡介苗的55个国家中,这两个数字分别是59.54和0.78。亚洲国家普遍新冠感染率较低,匪夷所思的越南就是一个例子,越南恰恰是普遍接种卡介苗的。

至于为什么,荷兰有研究者发文表示,卡介苗对人体免疫系统的“训练”,或许是对抗新冠病毒的重要机制。我们都知道,疫苗能帮助人体产生针对目标病原体的特异性免疫反应。可是,人体不单单只有抗体这种特异性免疫武器呀!大家别忘了咱们还有以白细胞为主力的非特异性免疫!过去有研究显示,卡介苗注射后似乎可长期刺激、训练白细胞,从而能强化人体非特异性免疫,起到增强人体对抗其他病原体的能力。

光靠这些臆测是不能就这么推广卡介苗的,所以就有了这个临床试验,已经经过了一期,二期,效果不错,现在就看这个对照双盲大标本的三期临床试验了。而打过卡介苗的国人们,也可以多点信心,散发点优越感,至少这是有科学依据的!而如果证实,那国内的那些严格监控措施可能实际上作用并不如预期的大,习大大不要那么傲娇!

 
后退
顶部